Muscat - Sultan Qaboos University's Medical Research Center and the drug manufacturing company Novartis signed a cooperation agreement to combat cardiovascular disease, one of the most important health challenges in the world.
This agreement seeks to reduce the prevalence of cardiovascular diseases and their associated risk factors in the Sultanate of Oman, with a focus on treating cases of high levels of cholesterol in the blood.
The two parties aim to benefit from advanced technologies and share best practices to develop innovative solutions that improve the management of cardiovascular diseases, with a focus on risk factors for high cholesterol levels.
Studies by the World Heart Federation indicated that these diseases cause 40 percent of all deaths in the country, and the two organizations intend to devote their joint experiences to make a tangible impact in this context, thus contributing to reducing the risks of high cholesterol levels.
Dr. Muhammad Ezz El-Din, Regional President for the Arabian Gulf Region at Novartis, said: "The cooperation with Sultan Qaboos University comes to make a tangible impact in the fight against cardiovascular diseases, and we developed a common vision to improve the lives of millions of people with these diseases"
For his part, Dr. Khalid bin Humaid Al Rasadi, Director of the Medical Research Center at Sultan Qaboos University, said: "We look forward to making a tangible impact in the efforts to combat cardiovascular diseases and improve the health and well-being of members of the Omani society."
The two organizations intend to launch educational programs that address the needs of healthcare professionals, patients and the wider community.